Isatuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Isatuximab: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma
One-Sentence Summary
Isatuximab is an anti-CD38 monoclonal antibody, originally used to treat plasma cell myeloma. The TxGNN model predicts it may be effective for indolent plasma cell myeloma, but there are currently 0 clinical trials and only 3 indirectly related publications (one review, two case-report/correspondence items), so the evidence is limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plasma cell myeloma |
| Predicted New Indication | Indolent plasma cell myeloma |
| TxGNN Prediction Score | 98.23% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, isatuximab is an anti-CD38 monoclonal antibody, its efficacy in plasma cell myeloma has been established through its marketed use, and mechanistically it may be applicable to indolent plasma cell myeloma.
Indolent (smoldering) myeloma is an earlier stage of the same plasma cell malignancy, and the clonal plasma cells express CD38. This gives the prediction a sound target-based rationale.
However, the high TxGNN score mainly reflects how close this disease is to the already approved indication. It is not independent clinical validation. The publications retrieved do not test efficacy in indolent myeloma (see below).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42488083 | 2026 | Review | American Journal of Blood Research | Reviews the roles of CD38 in the pathogenesis and treatment of B-cell lymphomas, including proliferation, apoptosis and immune modulation. Indirect relevance only. |
| 38888584 | 2024 | Case report | J Investig Allergol Clin Immunol | Successful desensitization to isatuximab in a patient with refractory multiple myeloma and indolent systemic mastocytosis. This is a hypersensitivity management report, not an efficacy study. |
| 38275249 | 2024 | Case report / Correspondence | J Investig Allergol Clin Immunol | Reply to the above case regarding isatuximab desensitization. Not an efficacy study. |
None of these publications is a prospective study of isatuximab in indolent or smoldering myeloma.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16630P | SARCLISA Concentrate for Solution for Infusion 20 mg/mL | Infusion, solution concentrate | Not stated in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-CD38 monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions. Haematological parameters (CBC) are generally reviewed in myeloma care. |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction query found 94 interacting drugs. Examples of those rated Major: deferiprone, samarium (153Sm) lexidronam, adalimumab and baricitinib. Examples rated Moderate include strontium chloride Sr-89, mercaptopurine, roflumilast, chloramphenicol, aldesleukin, alemtuzumab, anakinra, azathioprine, bendamustine, bleomycin, busulfan, canakinumab, capecitabine and carboplatin. Only a subset of the 94 interactions was available for review.
Package insert warnings and contraindications were not available. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The target rationale is plausible because indolent myeloma is an earlier stage of the same disease. However, there are no registered trials and no efficacy literature in this setting, so the evidence rests on model prediction (L5 by the standard rules; the underlying assessment of indirect literature suggests L4 at best). The high score mainly reflects proximity to the approved indication.
To proceed, the following is needed:
- Prospective or retrospective clinical data on isatuximab in indolent/smoldering myeloma, and a search for registered trials, including international registries
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications from HSA, to complete safety screening
- The approved indication text for the Singapore licence
- A risk-benefit assessment for treating early-stage disease, including infusion reactions, infection risk and interference with red cell serologic testing
- Review of the full list of drug interactions for co-medications likely in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.